3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Sarcoma
4
Gliosarcoma
4
Glioblastoma
4
Brain Neoplasms
3
Ovarian Neoplasms
2
Oligodendroglioma
2
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Soft Tissue Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Pharyngeal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lymphangioleiomyomatosis
1
Liposarcoma
1
Leiomyosarcoma
1
Hemangiosarcoma
1
Glioma
1
Interventions
Imatinib Mesylate
71
Sunitinib
31
regorafenib
17
nilotinib
15
ripretinib
13
avapritinib
7
Laparoscopy
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
CTLA-4 Antigen
4
Blood Specimen Collection
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Oxaliplatin
3
Observation
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Biopsy
3
Bevacizumab
3
trametinib
2
tanespimycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
Disulfides
×
Sarcoma
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts